Summit State Bank (SSBI) Forms $15.50 Double Top; Scynexis (SCYX) Sellers Increased By 8.49% Their Shorts

Summit State Bank (NASDAQ:SSBI) Logo

Summit State Bank (SSBI) formed double top with $15.97 target or 3.00% above today’s $15.50 share price. Summit State Bank (SSBI) has $91.93M valuation. The stock decreased 1.59% or $0.25 during the last trading session, reaching $15.5. About 1,380 shares traded. Summit State Bank (NASDAQ:SSBI) has risen 25.73% since June 23, 2017 and is uptrending. It has outperformed by 13.16% the S&P500. Some Historical SSBI News: 22/04/2018 – DJ Summit Bank, Inst Holders, 1Q 2018 (SBKO); 23/04/2018 – DJ 1st Summit Bancorp of Johnstown In, Inst Holders, 1Q 2018 (FSMK); 24/04/2018 – Summit State Bank Reports 98% Increase in Profitability and Declaration of Dividend; 24/04/2018 – Summit State Bank 2Q EPS 29c; 24/04/2018 – Correct: Summit State Bank 1Q EPS 29c, Not 2Q; 21/04/2018 DJ Summit State Bank, Inst Holders, 1Q 2018 (SSBI)

Scynexis Inc (NASDAQ:SCYX) had an increase of 8.49% in short interest. SCYX’s SI was 1.16M shares in June as released by FINRA. Its up 8.49% from 1.07 million shares previously. With 648,700 avg volume, 2 days are for Scynexis Inc (NASDAQ:SCYX)’s short sellers to cover SCYX’s short positions. The SI to Scynexis Inc’s float is 4.39%. It closed at $1.71 lastly. It is down 6.75% since June 23, 2017 and is uptrending. It has underperformed by 5.82% the S&P500. Some Historical SCYX News: 01/05/2018 – SCYNEXIS: Initiation of Phase 3 Registration Program in VVC Planned for the Fourth Qtr of 2018, With Potential NDA Filing in 2020; 13/03/2018 – SCYNEXIS Reports Full Yr 2017 Fincl Results and Provides Co Update; 08/05/2018 – SCYNEXIS 1Q Loss/Shr 12c; 13/03/2018 – CAXTON CORPORATION REPORTS 9.99 PCT PASSIVE STAKE IN SCYNEXIS INC AS OF MARCH 6, 2018 – SEC FILING; 23/05/2018 – SCYNEXIS to Participate in a Panel at the 2018 BIO International Convention; 07/05/2018 – SCYNEXIS Coverage Assumed by H.C. Wainwright at Buy; 20/03/2018 – SCYNEXIS Presents Data at Superbugs and Superdrugs 2018; 19/04/2018 – DJ SCYNEXIS Inc, Inst Holders, 1Q 2018 (SCYX); 01/05/2018 – SCYNEXIS: QIDP Provides Five Additional Years of Market Exclusivity, and Fast Track Expedites the Regulatory Path; 01/05/2018 – SCYNEXIS’s Oral SCY-078 Receives FDA QIDP And Fast Track Designations For The Treatment Of VVC And Prevention Of Recurrent VVC

Since March 8, 2018, it had 7 insider buys, and 0 sales for $246,885 activity. Sukenick Scott bought 2,959 shares worth $5,001. Angulo Gonzalez David also bought $24,995 worth of SCYNEXIS, Inc. (NASDAQ:SCYX) on Thursday, March 8. HASTINGS DAVID C had bought 11,834 shares worth $19,999 on Thursday, March 8. Another trade for 5,917 shares valued at $10,000 was made by Francois Eric on Thursday, March 8. Taglietti Marco had bought 100,000 shares worth $169,000.

Investors sentiment increased to 2.6 in 2018 Q1. Its up 1.17, from 1.43 in 2017Q4. It is positive, as 5 investors sold SCYNEXIS, Inc. shares while 5 reduced holdings. 16 funds opened positions while 10 raised stakes. 18.29 million shares or 114.32% more from 8.53 million shares in 2017Q4 were reported. Rock Springs Capital L P accumulated 820,000 shares. Rbf Capital Limited Liability Company has invested 0% of its portfolio in SCYNEXIS, Inc. (NASDAQ:SCYX). Jacobs Levy Equity Mgmt accumulated 35,800 shares. Wells Fargo Mn accumulated 1,000 shares. Private Advisor Grp Limited Com reported 200,000 shares stake. Federated Incorporated Pa has invested 0.03% of its portfolio in SCYNEXIS, Inc. (NASDAQ:SCYX). Armistice Capital Ltd holds 0.1% or 1.00 million shares. Spark Ltd Com holds 0% or 49,600 shares. Guggenheim Cap Limited Liability Corporation has 35,944 shares. Us National Bank & Trust De invested 0% in SCYNEXIS, Inc. (NASDAQ:SCYX). Goldman Sachs Grp owns 30,953 shares. Geode Cap Management Ltd owns 128,724 shares or 0% of their US portfolio. Acadian Asset Ltd reported 0% in SCYNEXIS, Inc. (NASDAQ:SCYX). National Bank & Trust Of New York Mellon holds 22,735 shares or 0% of its portfolio. Royal Natl Bank Of Canada, Ontario – Canada-based fund reported 4,100 shares.

SCYNEXIS, Inc., a drug development company, develops and commercializes anti-infectives to address unmet therapeutic needs. The company has market cap of $80.10 million. It is developing its lead product candidate, SCY-078, as a novel oral and intravenous drug for the treatment of various fungal infections, including serious and life-threatening invasive fungal infections. It currently has negative earnings. The firm also develops SCY-078, which is in various Phase I studies for the oral and intravenous formulations, as well as has completed Phase II study as a step-down therapy in patients with invasive candidiasis and vulvovaginal candidiasis.

More news for SCYNEXIS, Inc. (NASDAQ:SCYX) were recently published by: Seekingalpha.com, which released: “Your Daily Pharma Scoop: Scynexis Moves Up, Proteostasis Disappoints Investors, Cellectar Zooms” on June 11, 2018. Seekingalpha.com‘s article titled: “SCYNEXIS announces publication of early-stage SCY-078 data; shares up 2% premarket” and published on June 06, 2018 is yet another important article.

SCYNEXIS, Inc. (NASDAQ:SCYX) Institutional Positions Chart